LEADER 05231nam 2200637 450 001 9910460135303321 005 20200520144314.0 010 $a1-118-88994-0 035 $a(CKB)3710000000365738 035 $a(EBL)1895710 035 $a(SSID)ssj0001437628 035 $a(PQKBManifestationID)12630170 035 $a(PQKBTitleCode)TC0001437628 035 $a(PQKBWorkID)11372766 035 $a(PQKB)10927176 035 $a(MiAaPQ)EBC1895710 035 $a(DLC) 2015000334 035 $a(Au-PeEL)EBL1895710 035 $a(CaPaEBR)ebr11026086 035 $a(CaONFJC)MIL770050 035 $a(OCoLC)899267729 035 $a(EXLCZ)993710000000365738 100 $a20150310h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCardiovascular diseases $efrom molecular pharmacology to evidence-based therapeutics /$fY. Robert Li 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons Inc.,$d2015. 210 4$d©2015 215 $a1 online resource (504 p.) 300 $aIncludes index. 311 $a0-470-91537-4 320 $aIncludes bibliographical references and index. 327 $aTitle Page; Copyright Page; Contents; Preface; List of Abbreviations; Unit I General Introduction; Chapter 1 Introduction to Cardiovascular Diseases; 1.1 Overview; 1.2 Definition of Cardiovascular Diseases; 1.3 Classification of Cardiovascular Diseases; 1.3.1 Classification Based on Anatomical Location; 1.3.2 Classification Based on the Involvement of Atherosclerosis; 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification; 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases; 1.4.1 NCDs and Cardiovascular Diseases: The Global Status 327 $a1.4.2 The Status of Cardiovascular Diseases in the United States1.4.3 The Status of Cardiovascular Diseases in China; 1.5 Risk Factors of Cardiovascular Diseases; 1.5.1 Classification of Cardiovascular Disease Risk Factors; 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact; 1.6 Prevention and Control of Cardiovascular Diseases; 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level; 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases 327 $a1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health1.6.4 US DHSS "Million Hearts" Initiative; 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments; 1.7.1 Cardiovascular Risk Prediction; 1.7.2 Evidence-Based Treatments; 1.8 Summary of Chapter Key Points; 1.9 Self-Assessment Questions; References; Chapter 2 Introduction to Principles of Pharmacology; 2.1 Overview; 2.2 Definitions and History; 2.2.1 What Is Pharmacology?; 2.2.2 Definitions of Related Terms; 2.2.3 A Brief History of Pharmacology 327 $a2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology2.3.1 Drug Names, Sources, Preparations, and Administration; 2.3.2 Pharmacokinetics; 2.3.3 Pharmacodynamics; 2.3.4 Drug Toxicity; 2.3.5 Pharmacogenetics and Pharmacogenomics; 2.4 Principles of Drug Discovery, Development, and Regulation; 2.4.1 Definitions; 2.4.2 The Paradigm of Drug Creation and Survival; 2.4.3 The FDA Drug Review and Approval Process; 2.5 Pharmacology Subspecialties; 2.6 Introduction to Cardiovascular Pharmacology; 2.6.1 Definition and Scope; 2.6.2 New Developments and Challenges 327 $a2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases2.6.4 Polypill for the Management of Cardiovascular Diseases; 2.6.5 Protein Therapeutics of Cardiovascular Diseases; 2.6.6 Gene Therapy of Cardiovascular Diseases; 2.6.7 Stem Cell Therapy of Cardiovascular Diseases; 2.7 Summary of Chapter Key Points; 2.8 Self-Assessment Questions; References; Unit II Dyslipidemias; Chapter 3 Overview of Dyslipidemias and Drug Therapy; 3.1 Introduction; 3.2 Lipoprotein Metabolism; 3.2.1 Definition, Structure, and Classification of Lipoproteins 327 $a3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy 330 $aWritten in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology Includes guidelines and algorithms for pharmac 606 $aCardiovascular system$xDiseases$xChemotherapy 606 $aCardiovascular system$xDiseases$xDiagnosis 608 $aElectronic books. 615 0$aCardiovascular system$xDiseases$xChemotherapy. 615 0$aCardiovascular system$xDiseases$xDiagnosis. 676 $a616.1/061 700 $aLi$b Robert Y.$0866523 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460135303321 996 $aCardiovascular diseases$91934012 997 $aUNINA LEADER 01370nam 2200397Ka 450 001 9910696895303321 005 20080721154953.0 035 $a(CKB)5470000002381924 035 $a(OCoLC)234316277 035 $a(EXLCZ)995470000002381924 100 $a20080721d2008 ua 0 101 0 $aeng 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFood stamps and obesity$b[electronic resource] $ewhat do we know ?$fMichele Ver Ploeg and Katherine Ralston 210 1$a[Washington, D.C.] :$cU.S. Dept. of Agriculture, Economic Research Service,$d[2008] 215 $aiv, 31 pages $cdigital, PDF file 225 1 $aEconomic information bulletin ;$vno. 34 300 $aTitle from title screen (viewed on July 21, 2008). 300 $a"March 2008." 320 $aIncludes bibliographical references (pages 27-31). 517 $aFood stamps and obesity 606 $aFood stamps$zUnited States 606 $aObesity$zUnited States 615 0$aFood stamps 615 0$aObesity 700 $aVer Ploeg$b Michele$01085439 701 $aRalston$b Katherine$01398041 712 02$aUnited States.$bDepartment of Agriculture.$bEconomic Research Service. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910696895303321 996 $aFood stamps and obesity$93482995 997 $aUNINA LEADER 01685nas 2200481-a 450 001 996209299703316 005 20230506213019.0 035 $a(OCoLC)762004837 035 $a(CKB)2900000000000294 035 $a(CONSER)--2012267029 035 $a(MiAaPQ)616637 035 $a(DE-599)ZDB2578690-8 035 $a(EXLCZ)992900000000000294 100 $a20110210a20099999 --- - 101 0 $apor 135 $aur|n||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRevista ibero-americana de estratégia 210 $a[São Paulo] $cUniversidade Nove de Julho 300 $aRefereed/Peer-reviewed 311 $a2176-0756 330 $a"Mission: To serve as a vehicle for dissemination of theoretical and applied research in the strategy area broadly defined to include that study of strategy across organizations, nations, markets, and in society in general."--English Focus and scope page. 517 3 $aRIAE 517 3 $aIbero American strategy journal 517 3 $aRevista de estratégia ibero-americana 531 0 $aRev. Ibero-Am. Estratég. 606 $aStrategic planning$vPeriodicals 606 $aManagement$vPeriodicals 606 $aManagement$2fast$3(OCoLC)fst01007141 606 $aStrategic planning$2fast$3(OCoLC)fst01134371 608 $aPeriodicals.$2fast 610 0$aStrategy 615 0$aStrategic planning 615 0$aManagement 615 7$aManagement. 615 7$aStrategic planning. 712 02$aUniversidade Nove de Julho. 906 $aJOURNAL 912 $a996209299703316 996 $aRevista ibero-americana de estratégia$92124678 997 $aUNISA LEADER 02581 am 2200589 n 450 001 9910567797603321 005 20240104030717.0 010 $a979-1-03-000767-1 024 7 $a10.4000/books.pub.47479 035 $a(CKB)4100000012875264 035 $a(FrMaCLE)OB-pub-47479 035 $a(PPN)26327120X 035 $a(EXLCZ)994100000012875264 100 $a20220513j|||||||| ||| 0 101 0 $afre 135 $auu||||||m|||| 200 00$aDescription systématique du mbo$eLangue bantoue A.15$fChristiane Félicité Éwané 210 $aPessac$cPresses Universitaires de Bordeaux$d2021 215 $a1 online resource (332 p.) 311 $a979-1-03-000076-4 330 $aVoici un livre qui vient à son heure. C?est un heureux événement pour la langue mbo et pour la linguistique africaine. Grâce à la somme des données dégagées par la description, il ouvre, pour la langue mbo, des perspectives prometteuses en termes d?aménagement orthographique, terminologique et grammatical, ce qui ne manquera pas de faciliter son emploi dans tous les domaines de la vie moderne au bénéfice de ses usagers : alphabétisation, scolarisation, création littéraire, communication dans la presse, à la radio et à la télévision. Ce livre sera utile aux chercheurs car il constitue une contribution importante à la connaissance des langues bantoues de la zone A considérée par les spécialistes comme l?une des plus complexes et des moins explorées de l?ensemble du domaine. Enfin il s?adresse à la fois à ceux qui parlent le mbo et à ceux qui voudraient l?étudier ou l?enseigner. 606 $aLinguistics 606 $adescription linguistique 606 $asyntaxe 606 $aphonologie 606 $asynchronie 606 $alangue bantoue 606 $aethnonyme 606 $aglossonyme 606 $alangue à classes 606 $astructure syllabique 606 $atonologie 606 $amorphologie 615 4$aLinguistics 615 4$adescription linguistique 615 4$asyntaxe 615 4$aphonologie 615 4$asynchronie 615 4$alangue bantoue 615 4$aethnonyme 615 4$aglossonyme 615 4$alangue à classes 615 4$astructure syllabique 615 4$atonologie 615 4$amorphologie 700 $aÉwané$b Christiane Félicité$01458386 701 $aMusanji$b Ngalasso-Mwatha$01458387 801 0$bFR-FrMaCLE 906 $aBOOK 912 $a9910567797603321 996 $aDescription systématique du mbo$93658267 997 $aUNINA LEADER 02919oam 2200577I 450 001 9910823019003321 005 20240314024459.0 010 $a0-429-16843-8 010 $a1-4665-8714-8 024 7 $a10.1201/b15301 035 $a(CKB)2670000000394615 035 $a(EBL)1335842 035 $a(OCoLC)855504706 035 $a(SSID)ssj0000876664 035 $a(PQKBManifestationID)11535867 035 $a(PQKBTitleCode)TC0000876664 035 $a(PQKBWorkID)10923356 035 $a(PQKB)10353397 035 $a(OCoLC)857081231 035 $a(MiAaPQ)EBC1335842 035 $a(OCoLC)853508638 035 $a(EXLCZ)992670000000394615 100 $a20180331d2014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aBiomarkers in cardiovascular diseases /$feditors, Dimitris Tousoulis, Christodoulos Stefanadis 205 $a1st ed. 210 1$aBoca Raton :$cCRC Press,$d2014. 215 $a1 online resource (450 p.) 300 $aDescription based upon print version of record. 311 $a1-4665-8715-6 320 $aIncludes bibliographical references and index. 327 $apt. 1. Classical biomarkers -- pt. 2. Novel biomarkers. 330 $aThe establishment of precise and reliable biomarker tests for the early stages of cardiovascular disease is of great importance and can be the cornerstone in the prevention of future cardiovascular disease (CVD). Furthermore, some biomarkers may provide important information concerning the pathogenesis of CVD or appear to be useful in risk stratification, in CVD diagnosis, or in monitoring therapy; many others may be risk factors themselves, representing therefore potential targets of therapy. The ideal biomarker should have the following characteristics: highly sensitive, specific, reliable, accessible, standardized, dependable, cost effective, and easily interpretable by clinicians. The present book focuses on the presentation and evaluation of the most promising classical and novel biochemical markers used in CVD (coronary artery disease, hypertension, heart failure, hyperlipidemia, peripheral arterial disease). The underlying pathophysiological characteristics of each biomarker, as well as potential clinical implications in daily practice are reviewed in this book--Provided by publisher. 606 $aCardiovascular system$xDiseases$xDiagnosis 606 $aCardiovascular system$xDiseases$xPrevention 615 0$aCardiovascular system$xDiseases$xDiagnosis. 615 0$aCardiovascular system$xDiseases$xPrevention. 676 $a616.1075 701 $aTousoulis$b Dimitris$0897327 701 $aStefanadis$b Christodoulos$01600452 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910823019003321 996 $aBiomarkers in cardiovascular diseases$93923551 997 $aUNINA LEADER 05591oam 22010934 450 001 9910826443603321 005 20240402023454.0 010 $a1-4623-7092-6 010 $a1-4518-7104-X 010 $a9786612841972 010 $a1-4527-9649-1 010 $a1-282-84197-1 035 $a(CKB)3170000000055141 035 $a(EBL)1586706 035 $a(SSID)ssj0000944133 035 $a(PQKBManifestationID)11518474 035 $a(PQKBTitleCode)TC0000944133 035 $a(PQKBWorkID)10983294 035 $a(PQKB)11410749 035 $a(OCoLC)762062544 035 $a(IMF)WPIEE2008246 035 $a(MiAaPQ)EBC1586706 035 $a(EXLCZ)993170000000055141 100 $a20020129d2008 uf 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGlobalization Drives Strategic Product Switching /$fMarialuz Moreno Badia, Veerle Slootmaekers, Ilke Van Beveren 205 $a1st ed. 210 1$aWashington, D.C. :$cInternational Monetary Fund,$d2008. 215 $a1 online resource (68 p.) 225 1 $aIMF Working Papers 225 0$aIMF working paper ;$vWP/08/246 300 $aDescription based upon print version of record. 311 $a1-4519-1557-8 320 $aIncludes bibliographical references. 327 $aCover Page; Title Page; Copyright Page; Contents; I. Introduction; II. Industry Dynamics in Estonia; 1. Exits and Industry Switches, 1997-2004; 2. Sector Distribution; 3. Four-Digit Product Switches Decomposed25; 4. Destination of Product Switches by Technology Class; III. Determinants of Firm Dynamics; 5. Summary Statistics; A. Firm Characteristics; B. Product Market Characteristics: Domestic Market; C. Product Market Characteristics: International Competition; IV. Results; A. Baseline Results; 6. Baseline Specification; B. Self-Selection into New Markets 327 $a7. Product Switching Versus Industry Switching8. Industry Switching: Manufacturing versus Services; 9. Unit Value Difference Between Industry of Origin and Destination; V. Robustness Checks; A. Results by Size Class; 1. Sample Size Distribution; 10. Determinants of Firm Dynamics Across Size Categories; B. Results by Time Period; 11. Determinants of Firm Dynamics Across Time; VI. Conclusions; Appendix I. Data and Sample Selection; Appendix II. Definitions of Variables; Appendix III. Sector Classification According to Technology Intensity and Knowledge; References; Footnotes 330 3 $aUsing firm-level data for Estonia for the years 1997-2005, we analyze the impact of international competition on firm dynamics, considering both firm closedown and product switching. We contribute to the literature in two important ways: (1) this is the first paper to study the determinants of exit and product switching in an emerging market; and (2) we consider explicitly the role of export opportunities. Our results indicate that globalization does not affect firm exit significantly but it is an important factor explaining product switching. Previous studies on industrial countries have shown that product switching has been a defensive strategy against low-cost imports. In contrast, our results suggest that Estonian firms have switched products as an offensive strategy to take advantage of the export opportunities created by trade liberalization. 410 0$aIMF Working Papers; Working Paper ;$vNo. 2008/246 606 $aGlobalization$xEconomic aspects$zEstonia$xEconometric models 606 $aProduct management$zEstonia$xEconometric models 606 $aCosts, Industrial$zEstonia$xEconometric models 606 $aExports and Imports$2imf 606 $aFinance: General$2imf 606 $aIndustries: Manufacturing$2imf 606 $aTrade: General$2imf 606 $aGeneral Financial Markets: General (includes Measurement and Data)$2imf 606 $aIndustry Studies: Manufacturing: General$2imf 606 $aInternational economics$2imf 606 $aFinance$2imf 606 $aManufacturing industries$2imf 606 $aExports$2imf 606 $aCommodity markets$2imf 606 $aCompetition$2imf 606 $aManufacturing$2imf 606 $aImports$2imf 606 $aInternational trade$2imf 606 $aFinancial markets$2imf 606 $aEconomic sectors$2imf 606 $aCommodity exchanges$2imf 607 $aEstonia, Republic of$2imf 615 0$aGlobalization$xEconomic aspects$xEconometric models. 615 0$aProduct management$xEconometric models. 615 0$aCosts, Industrial$xEconometric models. 615 7$aExports and Imports 615 7$aFinance: General 615 7$aIndustries: Manufacturing 615 7$aTrade: General 615 7$aGeneral Financial Markets: General (includes Measurement and Data) 615 7$aIndustry Studies: Manufacturing: General 615 7$aInternational economics 615 7$aFinance 615 7$aManufacturing industries 615 7$aExports 615 7$aCommodity markets 615 7$aCompetition 615 7$aManufacturing 615 7$aImports 615 7$aInternational trade 615 7$aFinancial markets 615 7$aEconomic sectors 615 7$aCommodity exchanges 676 $a337 700 $aMoreno Badia$b Marialuz$01123353 701 $aSlootmaekers$b Veerle$01643720 701 $aBeveren$b Ilke Van$01700325 801 0$bDcWaIMF 906 $aBOOK 912 $a9910826443603321 996 $aGlobalization Drives Strategic Product Switching$94083251 997 $aUNINA